AI Article Synopsis
- The study examines how the humoral response (antibody production) after the first two doses of the BNT162b2 COVID-19 vaccine can predict responses to subsequent booster shots.
- Researchers followed hospital health care workers who received three vaccine doses and conducted serological tests to measure antibody levels at different intervals.
- Findings indicate that lower antibody levels and rapid declines in antibody levels after the second dose are strong indicators of a similarly low response to booster vaccinations.
Article Abstract
Background: Waning immunity after the coronavirus disease 2019 (COVID-19) vaccinations creates the constant need of boosters. Predicting individual responses to booster vaccines can help in its timely administration. We hypothesized that the humoral response to the first two doses of the BNT162b2 vaccine can predict the response to the booster vaccine.
Methods: A prospective cohort of hospital health care workers (HCW) that received three doses of the BNT162b2 vaccine. Participants completed serological tests at 1 and 6 months after the second vaccine dose and 1 month after the third. We analyzed predictive factors of antibody levels after the booster using multivariate regression analyses.
Results: From 289 eligible HCW, 89 (31%) completed the follow-up. Mean age was 48 (±10) and 46 (52%) had daily interaction with patients. The mean (±standard deviation) antibody level 1 month after the second vaccine was 223 (±59) AU/ml, and 31 (35%) had a rapid antibody decline (>50%) in 6 months. Low antibody levels 1 month after the second vaccine and a rapid antibody decline were independent predictors of low antibody levels after the booster vaccine.
Conclusions: The characteristics of the humoral response to COVID-19 vaccinations show promise in predicting the humoral response to the booster vaccines.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/pubmed/fdad198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunogenicity of the CoronaVac vaccine in children: a real-world study.
Front Immunol
January 2025
Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, Colombia.
Background: Despite its proven effectiveness and safety, there are limited real-world data on CoronaVac's immunogenicity in children, especially in lower-income countries, particularly for SARS-CoV-2 variants. We present a real-world study evaluating CoronaVac's immunogenicity in Colombian children stratified by previous exposure to this virus.
Methods: 89 children aged 3-11 years were enrolled (50 Non-Exposed and 39 Exposed).
Unique humoral immune response of pigs to repeated natural Japanese encephalitis virus infections: an amplifying host perspective.
Arch Virol
January 2025
Division of Veterinary Public Health, ICAR- Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India.
Japanese encephalitis virus (JEV) is the leading cause of viral encephalitis in the Asia-Pacific region. Amplification of JEV in pigs is a potent driver for spillover of the infection to humans, and hence monitoring of virus dynamics in pigs can provide insights into JEV ecology. To study the dynamics of natural JEV infection in a tropical region, two groups of immunologically naïve pigs consisting of six animals per group were kept as sentinels on two different farms in the district of Thanjavur, Tamil Nadu, India.
View Article and Find Full Text PDFCore-genome guided novel therapeutic targets identification and chimeric vaccine designing against Rickettsia rickettsii.
Sci Rep
January 2025
Department of Biochemistry, Bahauddin Zakariya University, Multan, 66000, Punjab, Pakistan.
Rocky Mountain Spotted Fever, caused by the gram-negative intracellular bacteria Rickettsia rickettsii, is a serious tick-borne infection with a fatality rate of 20-30%, if not treated. Since it is the most serious rickettsial disease in North America, modified prevention and treatment strategies are of critical importance. In order to find new therapeutic targets and create multiepitope vaccines, this study integrated subtractive proteomics with reverse vaccinology.
View Article and Find Full Text PDFA low pre-existing anti-NS1 humoral immunity to DENV is associated with microcephaly development after gestational ZIKV exposure.
PLoS Negl Trop Dis
January 2025
División de Inmunología, Programa de Medicina, Facultad de Ciencias de la Salud, Universidad Surcolombiana, Neiva, Huila, Colombia.
Background: Gestational Zika virus (ZIKV) infection is associated with the development of congenital Zika syndrome (CZS), which includes microcephaly and fetal demise. The magnitude and quality of orthoflavivirus-specific humoral immunity have been previously linked to the development of CZS. However, the role of ZIKV NS1-specific humoral immunity in mothers and children with prenatal ZIKV exposure and CZS remains undefined.
View Article and Find Full Text PDFThe emerging of emergent SARS-CoV-2 subvariants has reduced the protective efficacy of COVID-19 vaccines. Therefore, novel COVID-19 vaccines targeting these emergent variants are needed. We designed and prepared CoV072, an mRNA-based vaccine against SARS-CoV-2 Omicron (EG.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!